References of "Neate, C"
     in
Bookmark and Share    
Full Text
See detailReduction in bone remodelling markers with monthly oral ibandronate (150 mg) and weekly alendronate (70 mg): results from the motion study
Collette, Julien ULg; Reginster, Jean-Yves ULg; Zerbini, C. et al

in Osteoporosis International (2008, April), 19(Suppl.1), 207

Detailed reference viewed: 5 (0 ULg)
Full Text
See detailOral ibandronate (150 mg) continues to be effective and well tolerated when administered monthly: the mobile study long-term extension
Stakkestad, J. A.; Lorenc, R.; Czerwinski, E. et al

in Osteoporosis International (2007, March), 18(Suppl.1), 135-136

Detailed reference viewed: 3 (0 ULg)
Full Text
See detailIntermittent intravenous (i.v.) ibandronate injections are more effective than an established daily oral regimen: DIVA 2-year results
Czerwinski, E.; Reginster, Jean-Yves ULg; Jonkanski, I. et al

in Osteoporosis International (2007, March), 18(Suppl.1), 127

Detailed reference viewed: 2 (0 ULg)
Full Text
See detailClinical comparison in BMD gains with monthly oral ibandronate (150 mg) and weekly oral alendronate (70 mg) : results from the MOTION study
Miller, P. D.; Zerbini, C. A. F.; Recker, R. R. et al

in Journal of Bone and Mineral Research (2007), 22(S1), 451

Detailed reference viewed: 7 (1 ULg)
Full Text
See detailProgressive bone density gains with once-monthly oral ibandronate: the MOBILE study long-term extension
Lewiecki, EM; Reginster, Jean-Yves ULg; Elizondo-Alanis, LJ et al

in Arthritis and Rheumatism (2006, November), 54

Detailed reference viewed: 12 (8 ULg)